Newcastle Disease Ndv Infectious Bronchitis Ibv Vaccine for Poultry Use

Name: Newcastle Disease Ndv Infectious Bronchitis Ibv Vaccine for Poultry Use
Brand: Shandong Sinder Technology Co., Ltd
SKU: 1973719112

Shandong, ChinaShandong Sinder Technology Co., Ltd

US$0.10-30.00

10,000 vial

Sample price:US$0.10/sample.Request sample

Product profile

Customization

Available

Varieties

Vaccine

Component

Virus

Model NO.

HB1+H120

Type

The First Class

Pharmacodynamic Influential Factors

Temperature

Storage Method

Prevent High or LowTemperature

Veterinary Reg. No.

010372021

Usage

Nasal Dropping or Drinking Water Vaccination

Shelf Life

18 Months

Temperature

2-8℃

Withdrawal Period

0 Day

Package

1000 Doses/Vial, 2000 Doses/Vial, 5000 Doses/Vial

Transport Package

Air Way/Sea Way

Specification

2000 dose/vial

Trademark

SINDER

Origin

Beijing, China

HS Code

30024200

Production Capacity

100000L/Year

Company profile

Shandong Sinder Technology Co., Ltd

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2013-03-01 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T

AI-Powered supplier vetting

SummaryShandong Sinder Technology Co., Ltd. is a China-based foreign joint venture established in 1999, with 1,200 employees and operations focused on animal health, vaccines, medicines, feed additives, and herbal products. The available information indicates substantial production capacity, including nine production lines and stated annual outputs for vaccines, medicines, feed additives, and herbal products. It holds ISO9001:2015 and ISO14001:2015 certifications, and its disclosed R&D and quality-control staffing supports technical and quality capabilities. Innovation evidence includes large-scale cell suspension culture for highly pathogenic avian influenza vaccines. Export activity is documented from 2013, with markets across multiple regions, although exports represent only 1%–10% of total sales. Evidence is insufficient to assess after-sales service, customization capability, and broader customer-case depth. Financial credibility cannot be assessed because financial figures are excluded.

Supplier typeThe supplier is identified as Shandong Sinder Technology Co., Ltd., a China-based foreign joint venture established in 1999. Its business scope covers health and medicine, chemicals, agriculture and food, with product keywords centered on animal vaccines, veterinary medicines, feed additives, detection kits, and herbal products.

CertificationsThe supplier information explicitly lists ISO9001:2015 and ISO14001:2015 certificates, along with other unspecified certifications. This provides direct evidence of certified quality-management and environmental-management systems.

R&D capabilityThe supplier reports 154 R&D engineers, and its company description states that it was the first worldwide to achieve large-scale cell suspension culture of highly pathogenic avian influenza vaccine for animals. The disclosed production workshop was also described as the first approved by China’s Ministry of Agriculture and Rural Affairs for this technology, providing strong evidence of specialized innovation capability.

Production capacityThe supplier operates nine production lines, has a 73,279 m² manufacturing plant, employs 1,200 people, and reports annual outputs of 2,000 tons each for live and killed vaccines, 4,000 tons of medicine, 10,000 tons of feed additives, and 5,000 tons of herbal products. These stated facilities, workforce, production lines, and output figures directly support substantial production capability.

Client casesThree transaction records identify CÔNG TY TNHH THƯƠNG MẠI ANIVACC in Vietnam as an associated buyer, involving PCV2-related pig vaccine products and at least one recorded transaction. This confirms a documented buyer relationship, but the evidence is limited to one named buyer and does not demonstrate a broad portfolio of customer cases or project outcomes.